D.E. Shaw & Co’s Kyntra Bio KYNB Stock Holding History

D.E. Shaw & Co’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-400	Closed	-$405K	–	3938
2020 Q2	$405K	Buy	+400	New	+$371K	﹤0.01%	3492

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

GFG Capital Miami, Florida $363M AUM 45.53% 1-Year Est. Return

D.E. Shaw & Co's KYNB Position: Q3 2024 in Review

D.E. Shaw & Co sold out of Kyntra Bio (KYNB) in Q3 2024, closing a stake of 407 shares — an estimated $9.09K sold.

D.E. Shaw & Co first reported a position in KYNB in Q4 2014 and held it in 26 quarters. The position peaked at $7.58M in Q4 2018. 70 funds tracked by Wall St. Rank hold KYNB as of Q3 2024.

D.E. Shaw & Co reported no remaining Kyntra Bio position as of Q3 2024 after selling out during the quarter.
D.E. Shaw & Co sold 407 Kyntra Bio shares in Q3 2024, an estimated $9.09K.
D.E. Shaw & Co first reported a position in Kyntra Bio in Q4 2014 and held it in 26 quarters.
D.E. Shaw & Co's Kyntra Bio position peaked at $7.58M in Q4 2018.
70 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2024.

Based on D.E. Shaw & Co's 13F filing for Q3 2024, filed 14 Nov 2024.